top of page



The multidisciplinary research of our unit of excellence is reflected by collaborations between different groups belonging to the field of applied physics, applied mathematics, electronic engineering, bioinformatics, medical bioengineering, organic and pharmaceutical chemistry, pharmacology, biotechnology or experimental oncology among others. This multidisciplinarity has allowed an innovative research and the transference through the protection of knowledge in order to facilitate the use, application and exploitation outside the academic field, either with other R & D institutions, the productive sector or society in general. We have generated technological innovations, patents or utility models and even the creation of new

start-up and new Spinoffs.

Moreover, several members of the Unit are enrolled in the “Technology Promoters” pilot program of the TTO (Technology Transfer Office) of the University of Granada. At the moment, they have attending skill training activities and initiatives in innovation management, technology transfer, 

marketing and plan business that include topics about valorization and protection of research results, for instance, patents and utility models or the use of databases as sources of patent technology information.

We have a special interest in offering a necessary specialist training and invaluable expert mentoring for to develop and improve the valorization plan of the technology developed by the Unit. Also, we have as an objective for our PhD students and postdoctoral researcher to offer the possibility of establishing contact with businesses, entrepreneurs and investor that can give us the opportunity to elaborate an adequate commercialization/business plan that facilitates a possible spin-off /start-up creation. Definitely, we are convincing that our Mnat Unit must also require the transformation of scientific knowledge into a product that creates value in the society, increasing its success probabilities and facilitating access to markets for the benefit of the patients.

Cartilage 3D Scaffold.png

Polynucleotide for T cell specific transgen expression

Number: GENYO_19005

Date: 2020


CRISPNA, a new tool for genome editing and diagnosis

Number: P202031322

Date: 30/12/2020


Polinucleótido para expresión fisiológica en células T

Number: P202030955

Date: 2020


Composiciones para el tratamiento del cáncer, y específicamente de los sarcomas

Number: P202030148

Date: 2020


Método para predecir o pronosticar la respuesta al tratamiento del cáncer

Number: P202030147; WO2014122353

Date: 2020


Transistor FET reconfigurable con dopado dual

Number: P202030318

Date: 20/04/2020


Procedimiento de detección de radiación y partículas empleando un diodo semiconductor por modulación de bandas de energía

Number: P201831304

Date: 30/12/2018


Suspensiones Bimodales dentro del Límite Multidominio con Efecto Magneto-reológico Mejorado

Number: P201830726

Date: 18/07/2018


Polynucleotide for safer and more effective immunotherapies

Number: PCT/EP2019/081346; WO2020099572

Date: 2018

Licensed by LentiStem Biotech


Cancer treatment

Number: WO2017127892 A1; PCT/AU2017/050065

Date: 03/08/2017

Licensed by Propanc Biopharma, Inc


Ultrasonic low-frequency bioreactor as a selective therapy against cancer

Number: IPR-678

Date: 29/05/2017


Ultrasonic low frequency portable device for selective tumor therapy

Number: IPR-701

Date: 18/04/2017


Dispositivo transluminaly procedimiento para caracterización mecánica de estructuras

Number: P201730415

Date: 24/03/2017


Research &
Development Contracts

Using Engineered DNA to Assess Spatial and Temporal Variation in eDNA as a Measure of the Temporal and Spatial Variation of Biodiversity

Source of funding: UNITED STATES ARMY, U.S. ARMY CORP OF ENGINEERS through Cornell University USA

Reference: Contract OTRI (C4767-00)

PI: Francisco J. Rueda (UGR)

Funding: 83.660,00 $

Duration: 01/01/2021 - 19/09/2023


Bioimpresión 3D de cartílago y hueso con biotintas basadas en matriz descelularizada (dECM) para la regeneración de lesiones osteocondrales

Source of funding: Fundación Mutua Madrileña

Reference: FMM-AP17196-2019

PI: Elena López Ruiz

Funding: 120.000,00 €

Duration: 01/10/2019 - 30/09/2022


Valorización de plataforma de inmunoterapia

Source of funding: Fundación para la Innovación y la Prospectiva en Salud en España (FIPSE)

Reference: 3939-2

PI: Francisco Martín Molina

Funding: 29.000,00 €

Duration: 01/01/2021 - 31/12/2021


Development of biotinks and new marketable three-dimensional meshes for 3D bioprinting with application in regenerative medicine and cell therapy

Source of funding: Bioibérica (Barcelona)


PI: Juan Antonio Marchal

Funding: 81.200,00 €

Duration: 01/01/2012 - 31/12/2021


Detección RApida de INmunoglobulinas (IgA secretora, IgGs e IgMs) para el diagnóstico precoz del SARS-COV-2 mediante un biosensor portátil de grafeno

Source of funding: Fondo Supera COVID, CRUE-Banco Santander

Reference: DRAINCOV

PI: Francisco Gamiz

Funding: 110.000,00 €

Duration: 01/08/2020 - 31/10/2021


Identifying tissue and allele-specific vulnerabilities in oncogenic KRAS signaling

Source of funding: Revolution Medicine Inc. (RevMED)


PI: Lukas E Dow

Funding: 765.435,00 $

Duration: 01/07/2020 - 01/07/2021


Toxina HokD como nueva herramienta terapéutica frente a células madre cancerígenas derivadas de pacientes con cáncer de útero

Source of funding: Fundación Mutua Madrileña

Reference: FMM-AP16683-2017

PI: Houria Boulaiz Tassi

Funding: 121.690,00 €

Duration: 01/07/2017 - 30/06/2021


Tratamiento combinado con hiperoxia e inhibidores de PARP para contrarrestar la progresión tumoral mediada por hipoxia

Source of funding: Fundación Domingo Martínez


PI: Javier Oliver Pozo

Funding: 100.000,00 €

Duration: 01/06/2019 - 31/05/2021


Dispositivo diagnostico 'Point of Care' para la deteccion RAPida de la COVID19

Source of funding: Fondo Supera COVID, CRUE-Banco Santander

Reference: RAPID-19

PI: Francisco Gamiz

Funding: 95.000,00 €

Duration: 15/06/2020 - 17/05/2021


Epi-transcriptomic small RNA modifications as predictive signatures for therapy response in Diffuse Large B cell Lymphoma

Source of funding: KWF - Dutch Cancer Society

Reference: rc476

PI: Danijela Koppers-Lalic, Daphne de Jong, Michael Hackenberg

Funding: 547.890,00 €

Duration: 01/03/2017 - 28/02/2021


Metabolic and Immunological Vulnerabilities of Colorectal Cancer

Source of funding: Stand Up to Cancer Foundation (SUC2)/ American Association of Cancer Research (AACR)

Reference: SU2C-AACR-DT22-17

PI: Lewis C Cantley (Weill Cornell Medicine)

Funding: 59.600,00 $ direct costs/year

Duration: 01/08/2019 - 31/07/2020


Desarrollo sintético de PRP y posterior validación del mismo

Source of funding: PROPANC BIOPHARMA (Australia)


PI: Macarena Perán Quesada

Funding: 91.754,00 €

Duration: 09/05/2018 - 09/05/2020


Extinciones Invisibles: Pérdida de diversidad en zonas áridas de la Península Ibérica como consecuencia de la expansión de especies vegetales asociadas al ser humano (ExIn)

Source of funding: Fundación BBVA


PI: José M. Gómez

Funding: 100.000,00 €

Duration: 01/01/2017 - 31/12/2019


Potential drug for colon cancer treatment designed against DNA Gquadruplex targets and selective through the use of glucose transporters

Source of funding: Worldwide Cancer Research (Scotland)

Reference: 16-0290

PI: Juan Carlos Morales, Co-Javier Oliver Pozo

Funding: 185.720,00 £

Duration: 01/01/2016  - 31/12/2018


Development of capacitorless 1T DRAM

Source of funding: Korea Institute of Science and Technology


PI: Francisco Gamiz

Funding: 22.968,00 €

Duration: 01/01/2018 - 31/12/2018


Impact of hydropower damming on the physics of sub-arctic lakes 

Source of funding: Energy Fund of the National Power Company in Iceland (Icelandic: Orkurannsóknasjóður Landsvirkjunar) through the University of Iceland 

Reference: Contract OTRI (C3958)

PI: Francisco J. Rueda

Funding: 17.259,80 €

Duration: 04/04/2018 - 30/06/2018


Design of Smart Lubricants Using the Inverse Ferrofluid Approach

Source of funding: TOTAL

Reference: U16-055

PI: Juan de Vicente Álvarez-Manzaneda

Funding: 97.200,00 €

Duration: 01/06/2017 - 30/05/2018


Generation tools for the expression of proteins in cell lines

Source of funding: Px’Pharmaceutics (Grenoble, France)


PI: Francisco Martin

Funding: 16.000,00 €

Duration: 12/02/2013 - 12/02/2018


Impact of hydropower damming on the physics of sub-arctic lakes 

Source of funding: Energy Fund of the National Power Company in Iceland (Icelandic: Orkurannsóknasjóður Landsvirkjunar) through the University of Iceland 

Reference: Contract FEUGR (C4334-00) with University of Granada

PI: Francisco J. Rueda

Funding: 23.074,95 €

Duration:  01/10/2016 - 31/12/2017


Determination of gene expression by microarray analyses after treatment with propanc formulations. Cell differentiation assays

Source of funding: Propanc Pty Ltd (Australia)


PI: Juan Antonio Marchal, Macarena Perán

Funding: 29.400,00 €

Duration: 01/01/2015 - 31/12/2017


Shh morphogen gradient in the developing vertebrate neural tuve

Source of funding: Wellcome Trust

Reference: 080630/Z/06/A

PI: Prof. Karen Page,  Dr. James Briscoe

Funding: 144.181,00 £

Duration: 01/02/2013 - 28/02/2017


Contrato de prestación de servicios

Source of funding: LentiStem Biotech  (Granada)


PI: Francisco Martin


Duration: 01/01/2019 - 


Contrato de licencia de explotación de las Patentes  EP13382080.3, P201631406  y  EP18380016.8

Source of funding: LentiStem Biotech (Granada)


PI: Francisco Martin


Duration: 01/06/2018 -


Associated Start-ups 
& Spinoffs

Regemat 3D (

PKR-Exogenetics SL (16/12/2016 - 31/12/2021)

Oritia & Boreas Wind Engineering (

LentiStem Biotech (


Photo by J. M. Melchor

bottom of page